Jacobio Pharma shared a post on LinkedIn:
“From Patients to Purpose: Welcoming Dr. Andrea Wang-Gillam as Co-CEO of Jacobio Pharma
We’re thrilled to welcome Dr. Andrea Wang-Gillam, as our Co-Chief Executive Officer, effective November 13, 2025.
Before joining the biopharma industry, Andrea spent years at Washington University in St. Louis treating patients with gastrointestinal cancers and conducting clinical research.
She often shared that her greatest satisfaction came when a patient lived months—or years—longer than expected, while maintaining a good quality of life. Yet she also saw, every day, how few effective therapies were available, especially for patients with advanced cancer.
That realization motivated her to focus on developing innovative treatments that can meaningfully improve the lives of patients with cancer.
At Jacobio, Andrea combines her patient-centered approach with strong scientific and strategic leadership to drive company’s oncology portfolio. Together with Dr. Yinxiang Wang, our founder and Chairman, she will co-lead Jacobio into its next phase of global growth and global impact.”
Andrea Wang-Gillam, Co-CEO of Jacobio Pharma, shared this post, adding:
“It is an honor and privilege to serve in this new role. I remain deeply committed to the patients who motivate our mission and give meaning to our work!”
More posts featuring Andrea Wang-Gillam.